Literature DB >> 20096459

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review.

Amer Beitinjaneh1, Sekwon Jang, Henri Roukoz, Navneet S Majhail.   

Abstract

The fms-like tyrosine kinase 3 (FLT3) gene aberrations, internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, are frequent in acute promyelocytic leukemia (APL). To evaluate their prognostic significance, we performed a systematic review and meta-analysis. Eleven studies covering a total of 1063 subjects were included in this review. Incidence of ITD and TKD mutations was 12-38% and 2-20%, respectively. In 9 of 11 studies, ITD was associated with high WBC count at the time of diagnosis, which is a known prognostic indicator in APL. Patients with ITD had inferior 3-year overall survival compared to patients without ITD (risk ratio 1.42, 95% CI: 1.04-1.95). Similarly, ITD was also associated with adverse 3-year disease-free survival (risk ratio 1.48, 95% CI: 1.02-2.15). There were only two studies that evaluated the association of TKD mutation in APL; both showed a trend towards worse survival in patients with mutated TKD. In conclusion, FLT3 ITD is associated with high WBC at diagnosis in patients with APL. Although the available literature is limited to observational studies, our systematic review suggests that FLT3 mutations, especially ITD, can adversely affect overall survival and disease-free survival in APL. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096459     DOI: 10.1016/j.leukres.2010.01.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  35 in total

1.  Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Authors:  Harry Iland; Ken Bradstock; John Seymour; Mark Hertzberg; Andrew Grigg; Kerry Taylor; John Catalano; Paul Cannell; Noemi Horvath; Sandra Deveridge; Peter Browett; Tim Brighton; Li Chong; Francisca Springall; Juliet Ayling; Alberto Catalano; Shane Supple; Marnie Collins; Juliana Di Iulio; John Reynolds
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

2.  FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.

Authors:  Massimo Breccia; Giuseppina Loglisci; Maria Giovanna Loglisci; Roberto Ricci; Daniela Diverio; Roberto Latagliata; Robin Foà; Francesco Lo-Coco
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

3.  Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

4.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors:  Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

5.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

Authors:  Robert E Gallagher; Barry K Moser; Janis Racevskis; Xavier Poiré; Clara D Bloomfield; Andrew J Carroll; Rhett P Ketterling; Diane Roulston; Esther Schachter-Tokarz; Da-Cheng Zhou; I-Ming L Chen; Richard Harvey; Greg Koval; Dorie A Sher; James H Feusner; Martin S Tallman; Richard A Larson; Bayard L Powell; Frederick R Appelbaum; Elisabeth Paietta; Cheryl L Willman; Wendy Stock
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

6.  Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations.

Authors:  Harshabad Singh; Lillian Werner; Daniel Deangelo; Karen Ballen; Philip Amrein; Martha Wadleigh; Donna Neuberg; Edward Fox; Richard Stone; Eyal Attar
Journal:  Am J Hematol       Date:  2010-12       Impact factor: 10.047

7.  Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Authors:  Eva Barragán; Pau Montesinos; Mireia Camos; Marcos González; Maria J Calasanz; José Román-Gómez; Maria T Gómez-Casares; Rosa Ayala; Javier López; Óscar Fuster; Dolors Colomer; Carmen Chillón; María J Larrayoz; Pedro Sánchez-Godoy; José González-Campos; Félix Manso; Maria L Amador; Edo Vellenga; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

8.  Clinical and pathologic features of secondary acute promyelocytic leukemia.

Authors:  Amy S Duffield; Joseph Aoki; Mark Levis; Kathleen Cowan; Christopher D Gocke; Kathleen H Burns; Michael J Borowitz; Milena Vuica-Ross
Journal:  Am J Clin Pathol       Date:  2012-03       Impact factor: 2.493

9.  Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.

Authors:  Yanfeng Liu; Pengcheng He; Feng Liu; Lili Shi; Huachao Zhu; Xiaoyan Cheng; Jing Zhao; Yuan Wang; Mei Zhang
Journal:  Mol Clin Oncol       Date:  2014-01-24

10.  Role of arsenic trioxide in acute promyelocytic leukemia.

Authors:  Harry J Iland; John F Seymour
Journal:  Curr Treat Options Oncol       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.